OVERVIEW
Before Recruitment, Build Representation
In mid-2022, Lightship partnered with Acclinate to increase African American representation in a phase 3 clinical trial for Alzheimer’s disease. Recognizing the need for a more diverse participant pool, the Lightship team engaged Acclinate’s expertise. The engagement spanned 4 months, and during this period, Acclinate aimed to double the number of pre-screened African Americans that Lightship had reached in the prior 12 months (43 people in total).
Lightship leveraged Acclinate’s three-staged approach, which combines community engagement through NOWINCLUDED with the predictive analytics tool, e-DICT. Lightship pre-screened 164 potential patients, and 157 of them identified as Black or African American. Acclinate’s efforts identified 86 patients who were eligible for screening.
Lightship leveraged Acclinate’s three-staged approach, which combines community engagement through NOWINCLUDED with the predictive analytics tool, e-DICT. Lightship pre-screened 164 potential patients, and 157 of them identified as Black or African American. Acclinate’s efforts identified 86 patients who were eligible for screening.
